2023 Access Clinical Trials Patients 
SpeedWeed
MAY 15, 2021
A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. For this study, researchers recruited 90 patients suffering from severe, chronic PTSD. Image via. This promising new study is helmed by Rick Doblin, Ph.D.
Cannabis Law Report
OCTOBER 4, 2021
One of the known beneficial uses of psilocybin is as a palliative care tool for patients with advanced illness who suffer from anxiety and/or depression. A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veriheal
MARCH 2, 2024
In December of 2023, the country recently made a new move towards reform that could stimulate the cannabidiol (CBD) industry and provide many patients, such as those with epilepsy , with access to potentially life-changing medical treatments. and Europe to treat severe epilepsy, as well as other medical conditions.
Veriheal
MARCH 20, 2023
Both Colorado and Oregon allow patients to take psilocybin under the supervision of regulated and licensed “healing centers.” While decriminalization decreases the negative impact of legal issues, it does not provide accessible, safe, and regulated psilocybin for those seeking treatment. Colorado has a wider range of psilocybin use.
Cannabis Law Report
JUNE 14, 2022
PAREA is a non-profit, multistakeholder and multidisciplinary partnership bringing together patient organizations, medical associations, scientific societies, psychedelic foundations, and the for-profit sector. The good news is that innovations that completely change the lives of patients continue to emerge.
Cannabis Law Report
AUGUST 7, 2021
We are currently focused on developing MDMA-assisted therapy as a Breakthrough Therapy for PTSD, with plans to submit for FDA approval in 2023. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. Key Responsibilities.
Cannabis Law Report
MAY 31, 2022
The first path, that of traditional medicine, currently offers patients limited options. The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. 2022 Active FDA Clinical Trials and State-Regulated Systems.
Expert insights. Personalized for you.
52 
Let's personalize your content